Gå till innehåll

Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Golimumab

Summary

Hazard - P - B - T - Risk Exempt

Assessment report

Assessment report for Simponi (golimumab) 13 December 2018, EMA/898638/2018.

Since golimumab is an antibody (i.e. a protein), the product is not expected to pose a risk to the environment when used according to the labelling. Therefore, it is considered acceptable that no formal ERA according to the EMA 2006 Guideline (corr. 2) is needed for golimumab.

Fass environmental information

Fass environmental information for Simponi from MSD (downloaded 2019-08-20).

The use of amino acids, proteins and peptides is not considered to have any environmental impact.

According to the European Medicines Agency guideline on environmental risk assessments for pharmaceuticals (EMA/CMP/SWP/4447/00), vitamins, electrolytes, amino acids, peptides, proteins, carbohydrates, lipids, vaccines and herbal medicinal products are exempted because they are unlikely to result in significant risk to the environment.

References

  1. European Medicines Agency. European public assessment reports (EPAR).
  2. Fass för vårdpersonal.
  3. European Medicines Agency, EMA: Committee for Medicinal Products for Human Use (CHMP). Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use. 1 June 2006.

Author: Health and Medical Care Administration, Region Stockholm